Belgium - UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the final three-year open-label extension (OLE) study results of FINTEPLA (fenfluramine) in Dravet syndrome are being presented at the International Child Neurology Congress (ICNC), May 6-10, 2024, in Cape Town, South Africa.

As of January 2023, 375 patients were enrolled in the OLE; 92 were 2 to =1 dose of fenfluramine. The data demonstrated that treatment with fenfluramine for up to 3 years in people living with Dravet syndrome was generally well tolerated, with no new or unexpected safety signals identified, and patients experiencing clinically significant, durable reductions in monthly convulsive seizure frequency (MCSF).

In the modified intent-to-treat (mITT) population (n=324), the median percent MCSF change from baseline over the entire OLE was -66.8%, P

(C) 2024 Electronic News Publishing, source ENP Newswire